Reading Room

Recommendations for Contraceptive Use

Previous PageNext PageTable Of Contents RH TOC


Cervical Cancer Prevention


Q.4. Has the use of family planning methods been shown to increase the risk of cervical cancer?

Answer

Rationale

a) Barrier methods of contraception help to decrease the risk of cervical cancer. a) In several studies, women reporting use of barrier methods (including condoms) appear to have a lower risk of cervical cancer. These findings have not been found in all studies, however. If cervical cancer is caused by a sexually transmitted disease (STD) such as HPV, it is plausible that barrier use will protect a woman from cervical cancer or pre-cancer, but she would need to use the barrier method whenever engaging in intercourse.
   
b) Intrauterine devices (IUDs) and tubal ligation do not increase the risk. b) Research has not found IUDs or tubal ligation to increase cervical cancer risk in comparison to using no method.
   
c) There remains concern that hormonal contraceptives are associated with a low level increased squamous cervical cancer risk. (There is stronger evidence for a relationship between oral contraceptives (OCs) and adenocarcinoma, a more rare form of cervical cancer than the squamous cell cancer.) c) Some researchers believe that long-term combined oral contraceptive (COC) use (beyond five years) may be associated with a slight increased risk of cervical cancer. Other researchers disagree, saying that this association may not be due to COCs, but may result if COC users receive better medical care and more frequent screening (screening biases), are not using barrier methods, are having more sexual partners, are initiating intercourse at an earlier age, or a number of other factors. Additionally, because COCs may increase cervical ectopy, it may be easier to get a positive Pap smear from a COC user.
  1. Feldblum P, Joanis C. Modern barrier methods: effective contraception and disease prevention. Durham, NC: Family Health International, 1994, p 24.
  2. La Vecchia C. Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical neoplasia. Contraception 1994;49:223-30.
  3. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstetrics and Gynecology 1995;85(5 pt 1):793-801.
  4. Swan S, Petitti D. A review of problems of bias and confounding in epidemiologic studies of cervical neoplasia and oral contraceptive use. American Journal of Epidemiology 1982;115(1):10-8.
  5. Thomas DB, Ray RM. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. Contraception 1995;52(5):307-12.
  6. World Health Organization. Improving access to quality care in family planning: eligibility criteria for contraceptive use. Geneva: WHO, 1996.
  7. WHO. Invasive squamous cell carcinoma and combined oral contraceptives: results from a multi-national study. International Journal of

Any part of Recommendations for Updating Selected Practices in Contraceptive Use may be reproduced or adapted to meet local needs without prior permission from the TG/CWG Secretariat, provided the TG/CWG is acknowledged and the material is made available free of charge or at cost.


| Home | Family Planning | Maternal & Neonatal Health | Cervical CancerRelated Health Topics
Tools for Trainers
| Reading Room | Related Links | Search ReproLine | Website Tools

Quick Search 

Website design copyright © 1995-2003 by JHPIEGO Corporation. All rights reserved.

Last Updated: 09 Jul 2003

URL: http://www.reproline.jhu.edu/
Reproductive Health Online (ReproLine): a family planning and reproductive health training website

Top Of Page